# Protalix BioTherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/protalix-biotherapeutics

- Industry: Biotechnology
- Headquarters: Karmiel, Israel
- Website: www.protalix.com
- Total disclosed funding: $5.3M
- Latest round: Series C (Jul 1, 2005)
- Investors on record: 3

## About

Protalix BioTherapeutics Inc. is an Israel-based biopharmaceutical company focused on developing and commercializing innovative enzyme replacement therapies to treat rare diseases.Protalix BioTherapeutics Inc. specializes in enzyme replacement therapies that cater to patients with rare genetic disorders. Founded in 1993 in Karmiel, Israel, the company became public through a reverse merger with Orthodontix, Inc. in December 2006. The firm has raised a total of USD 40.00 mn, most recently in a PIPE funding round in which Cybele Holdings participated. Protalix has successfully executed 11 deals, with its latest deal dated October 23, 2007.Protalix BioTherapeutics Inc. specializes in developing and commercializing innovative enzyme replacement therapies aimed at treating rare diseases. Their core product offerings include therapeutic proteins that address specific metabolic deficiencies caused by genetic disorders. Protalix's existing product portfolio includes two approved enzyme replacement therapies utilized by healthcare providers in North America, Europe, and other international markets, primarily serving patients and healthcare providers in need of these critical treatments.Protalix BioTherapeutics generated USD 38.35 mn in revenue for the year 2023, with an EBITDA of USD -16.67 mn. The company earns revenue through sales of its enzyme replacement therapies, engaging with healthcare institutions and pharmacies while ensuring that their products reach patients effectively.Protalix BioTherapeutics plans to utilize its recent funding to expand its product line and enter new markets. The company aims to launch additional enzyme replacement therapies within the next few years and is focusing on penetrating more geographic regions, particularly in Europe and Asia. Recent funding will support research and development initiatives, allowing Protalix to enhance its manufacturing capabilities and expand distribution networks. The strategic goal is to make therapies accessible to a broader patient population suffering from rare diseases.

## Funding rounds

- Series C, Jul 1, 2005, $5.3M — Tamares, Docor International Management, Atara Technology Ventures

## Investors

- Tamares (https://capitalatlas.ai/funds/tamares) — Series C
- Docor International Management (https://capitalatlas.ai/funds/docor-international-management) — Series C
- Atara Technology Ventures (https://capitalatlas.ai/funds/atara-technology-ventures) — Series C